TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02797548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin only
Description: Aspirin only during surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: No antiplatelet therapy
Description: No antiplatelet therapy will be during surgery
Study: NCT02933151

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Nutritional Supplement
Description: Selection of which supplement to give to the patients will be left to the dialysis unit's governing body as this study is not interested in a specific supplement's effect on nutrient restoration and subsequent outcomes but rather on oral replacement of amino acids regardless of the agent used.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Nutritional Supplement
Description: Selection of which supplement to give to the patients will be left to the dialysis unit's governing body as this study is not interested in a specific supplement's effect on nutrient restoration and subsequent outcomes but rather on oral replacement of amino acids regardless of the agent used.
Study: NCT01257243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Syrup of oxomemazine, guaifenesin and potassium iodate
Description: 5ml each 4 hours
Study: NCT02640716

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo program
Description: For the control group, tasks for processing speed and attention are included. Importantly, a fixed, primary difficulty level for all participants in the control group is set.
Study: NCT01682668

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral subthalamic stimulation
Study: NCT03590834

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based Intervention
Description: 1. Monthly interactive poster education sessions led by parent peer educators during child pick-up time. Held at Head Start Center. These sessions include family health challenges and take-home activities.~2. Three Home Visits delivered by Head Start staff. Obesity prevention goal-setting integrated into existing Head Start home visits~3. 16 semi-monthly, Family Newsletters with stories, tips, and strategies to promote healthy habits for preschool children~4. Incorporating activities related to PA, nutrition and sleep into existing Head Start Center Summer Calendars

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: Children will receive Head-Start-approved health education program for children: I Am Moving, I Am Learning. In addition, the investigators will deliver an early childhood literacy program to all active control children to increase buy-in and retention.
Study: NCT05135247

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 3 different types of training or control

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 3 different types of training or control

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 3 different types of training or control
Study: NCT04438603

Intervention type: DRUG
Intervention: Intervention for patients at high risk of disease progression
Description: BP-lowering goal of \< 125/75 mm Hg and treat with steroids or steroids combined with immunosuppressants based on optimal supportive therapy:~1. If GFR\>60 ml/min/1.73m\^2, oral prednisone 0.6-0.8 mg/kg/day ( (maximum dose 48 mg/day) for 2 months, followed by a monthly dose reduction of 8 mg for 24 weeks.~2. If GFR is 30-60 ml/min/1.73m\^2, intravenous cyclophosphamide (CTX) 750 mg per month per m\^2 for 6 months, along with oral prednisone (at the same dose as 1); if intravenous administration is unacceptable, then the above regimen was replaced with oral mycophenolate mofetil 500 mg bid for 24 weeks.
Study: NCT00733356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vyvanse
Description: Subjects will participate in an open-label dose optimization period and successful titration to an optimal dose of Vyvanse™, subjects will take their optimized dose of Vyvanse™ (30, 50 or 70 mg/day) during the week leading up to their final visit. During the study subjects will take their prescribed dose once a day in the morning with breakfast.
Study: NCT01869491

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Compound Sodium Alginate Double Action Chewable Tablets
Description: 2 tablets four times daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo tablets
Description: 2 tablets four times daily
Study: NCT02253667

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFONC

Intervention type: DEVICE
Group type: OTHER
Intervention: Conventional oxygen therapy
Study: NCT03099369

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily Step-based Exercise
Description: A 12-week step-based exercise prescription with the eventual goal of walking at least 5,000 steps a day.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Symptom-based Exercise
Description: A 12-week symptom-based exercise prescription adapted from clinical practice guidelines.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fitbit Fitness Monitor
Description: Used by the experimental group to assess outcome and to guide exercise therapy; used by the active comparator group to assess outcome only

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fitbit Fitness Monitor
Description: Used by the experimental group to assess outcome and to guide exercise therapy; used by the active comparator group to assess outcome only
Study: NCT01257243

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Syrup of guaifenesin
Description: 5ml each 4 hours
Study: NCT01451996

Intervention type: DRUG
Group type: OTHER
Intervention: Claritin
Description: Subject will be given 10mg Claritin tablet.

Intervention type: DRUG
Group type: OTHER
Intervention: Claritin
Description: Subject will be given 10mg Claritin tablet.
Study: NCT02725164

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxygen concentration
Description: oxygen concentration will be measured in the tracheal tube and oropharynx during spontaneous or controlled ventilation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oxygen concentration
Description: oxygen concentration will be measured in the tracheal tube and oropharynx during spontaneous or controlled ventilation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nitrous oxide concentration
Description: nitrous oxide concentration will be measured in the tracheal tube and oropharynx during spontaneous or controlled ventilation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: nitrous oxide concentration
Description: nitrous oxide concentration will be measured in the tracheal tube and oropharynx during spontaneous or controlled ventilation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carbon dioxide concentration
Description: carbon dioxide concentration will be measured from the tracheal tube and in the oropharynx during spontaneous or controlled ventilation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: carbon dioxide concentration
Description: carbon dioxide concentration will be measured from the tracheal tube and in the oropharynx during spontaneous or controlled ventilation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevoflurane concentration
Description: sevoflurane concentration will be measured in the tracheal tube and oropharynx during spontaneous or controlled ventilation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sevoflurane concentration
Description: sevoflurane concentration will be measured in the tracheal tube and oropharynx during spontaneous or controlled ventilation
Study: NCT03141216

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VCV+PSV
Description: invasive mechanical mechanical modes by volume cycling and by pressure support which the patients will be submitted to before weaning. Post-operative mechanical ventilation average time: 6 hours after ICU admission.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PCV+PSV
Description: invasive mechanical mechanical modes by pressure cycling and by pressure support which the patients will be submitted to before weaning. Post-operative mechanical ventilation average time: 6 hours after ICU admission.
Study: NCT01900457

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electromyography

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electroencephalography
Study: NCT05704010

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Video capsule endoscopy
Description: Video capsule endoscopy every 2 years
Study: NCT02697461

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intrinsic Foot Strengthening
Description: Intrinsic foot strengthening is a commonly used intervention in clinic used to increase foot stability both in prevention of and in treatment of foot and ankle injury. Subjects allocated to the strengthening program will be educated in commonly used short foot exercises and toe yoga maneuvers that target the intrinsic muscles of the foot. No equipment will be required to perform the exercises.
Study: NCT04708119

Intervention type: PROCEDURE
Group type: OTHER
Intervention: The follicular tissues were also excised after tooth extraction.
Description: The follicular tissues were also excised after tooth extraction. Soft tissue samples taken during surgical removal of ILTM were evaluated in the department of pathology.
Study: NCT04399837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spesolimab
Description: Solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spesolimab
Description: Solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spesolimab
Description: Solution for injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for injection
Study: NCT03143881

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Standardized information on the etiology of HF, mechanisms and side effects of medications prescribed, strategies for minimizing exacerbations, and warning signs of worsening clinical status will be discussed with the patient.
Study: NCT04623307

Intervention type: DIAGNOSTIC_TEST
Intervention: Non-contact DCS-Speckle multi-parameter imaging
Description: The protocol consists of 2-min resting, 6-min stationary state and 2-min resting, with monitoring data continuously by the DCS-Speckle.
Study: NCT02697461

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Joint Mobilization
Description: Joint mobilization is a commonly used clinical intervention used to decrease pain and increase joint range of motion. In the treatment groups who present with joint hypomobility, a forefoot inversion maneuver with a dorsally applied pressure in the lateral midfoot and rearfoot stabilized will be applied at the barrier before the physiologic end range of motion. A second mobilization will be performed at the distal segment of the 1st Tarsometatarsal joint. These mobilizations will be performed by a board certified orthopaedic physical therapist with 14-yrs of practice experience. No equipment will be required to perform the joint mobilization.
Study: NCT01313026

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous nerve evaluation
Description: Implantation of a nerve stimulator to stimulate the sacral nerve plexus

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous nerve evaluation
Description: Implantation of a nerve stimulator to stimulate the sacral nerve plexus
Study: NCT01013948

Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-Investigational Product (Survey Study)
Study: NCT04623307

Intervention type: DIAGNOSTIC_TEST
Intervention: Non-contact DCS-Speckle multi-parameter imaging
Description: The protocol consists of 2-min resting, 6-min stationary state and 2-min resting, with monitoring data continuously by the DCS-Speckle.

Intervention type: DIAGNOSTIC_TEST
Intervention: Non-contact DCS-Speckle multi-parameter imaging
Description: The protocol consists of 2-min resting, 6-min stationary state and 2-min resting, with monitoring data continuously by the DCS-Speckle.
Study: NCT00985855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin, vinorlebine, cetuximab
Description: patient will receive 2 cycles of cisplatine 80 mg/m² at day 29 and day 50 more vinorelbine 15 mg/m² at day 29, day 36 and day 50 and 57 associated to cetuximab 400 mg/m² at day: 22,29, 36, 43, 50, 57, 64 and 71

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatine, etoposide, cetuximab
Description: patient will receive 2 cycles of cisplatine 50 mg/m² at day 29, 36, 57, and 64 + étoposide 50mg/m² during day 29-33, day 57-61associated to cetuximab 400 mg/m² at day: 22,29, 36, 43, 50, 57, 64 and 71
Study: NCT03022305

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group one - standard therapy
Description: Group two - standard physical therapy treatment for shoulder and hip maladjustment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group two - neuromuscular therapy
Description: Use of physical therapy treatment for shoulder and hip maladjustment.
Study: NCT00198341

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiological Arm
Description: Clinical Visit + X-Ray Chest

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scannographic arm
Description: Clinical visit + X-Ray Chest + CT-Scan + Fibroscopy (for squamous cell)
Study: NCT03537768

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ulipristal Acetate
Description: UPA Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levonorgestrel
Description: LNG Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levonorgestrel
Description: LNG Tablet (x2)
Study: NCT01643915

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No distraction method
Description: Patients with conventional treatment. No distraction method during the treatment visits.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Distraction method
Description: Patients will see a cartoon film in a screen attached to the ceiling, just above the dental chair during the second treatment visit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Distraction method
Description: Patients will see a cartoon film with with Rimax® multimedia eyeglasses that occlude the environment partially during the second treatment visit.
Study: NCT04200859

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold application
Description: cold application using ice pack/gel pad in the control of pain experienced during chest tube removal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold application
Description: cold application using ice pack/gel pad in the control of pain experienced during chest tube removal
Study: NCT04105361

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Posterior neurectomy
Description: Cut of posterior nasal nerve

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Posterior neurectomy
Description: Cut of posterior nasal nerve
Study: NCT04501705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate
Description: Apatinib mesylate tablets: Orally, 500 mg, once a day, with warm water for half an hour after a meal (the time of taking the medicine every day should be the same as possible).~Continue to use 28 days as a cycle, medication until disease progression (PD), intolerable toxicity occurs or the patient withdraws informed consent. However, the longest period does not exceed 24 cycles, and the treatment after 24 cycles is determined by the investigator.
Study: NCT01713322

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain management education
Description: Parents are provided with educational material on how to manage child pain during immunization.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: No pain management education
Description: Control - parents receive general information about childhood immunization.
Study: NCT03242538

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pelvic Exercise
Description: Hip extension and external hip rotation exercises are completed prior to daily external beam radiation treatment.
Study: NCT02545595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex 1 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex 2 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex 4 mg/kg
Study: NCT00071994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02115672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-8040
Description: BL-8040 will be added to imatinib to improve CML response.
Study: NCT03823482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Administration of lidocaine 2% 4 mg/kg administered as regional anesthesia of the scalp prior to Mayfield frame placement and lidocaine 1% 40 mg topically to the throat prior to direct laryngoscopy and endotracheal intubation.
Study: NCT00945880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clemizole hydrochloride
Description: Two 50 mg capsules containing clemizole hydrochloride are to be administered orally twice a day for 28 days for a total daily dose of 200 mg. Followed immediately by standard of care treatment consisting of interferon and ribavirin
Study: NCT01913223

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nestis® jet injector system with a bi-functional catheter
Study: NCT01155505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide (CC-5013)
Description: CC-5013 given PO daily on D1-D14 every 21 days and Paclitaxel administered IV over 1 hour on d1 and 8 every 21 days until tumor progression or unacceptable toxicity
Study: NCT02225769

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Management of febrile children using e-POCT
Description: Use of the e-POCT tool by study clinicians for the clinical management of febrile episodes. The e-POCT tool is an electronic algorithm that integrates key clinical elements with the results of malaria and host biomarkers point-of-care test results (including oximetry).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Management of febrile children using ALMANACH
Description: Management of febrile children by study clinicians using ALMANACH. ALMANACH is an improved IMCI algorithm on mobile phone or tablet
Study: NCT02082782

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Irreversible electroporation (IRE)
Description: Percutaneous (CT-guided) or open (US-guided) irreversible electroporation of central colorectal liver metastasis.
Study: NCT01157494

Intervention type: OTHER
Intervention: classification of hand manipulation function
Description: To determine the criterion validity of the classification of the pattern of manipulation proposed by Ferrari et al. we correlated hand manipulation classes with both the scores of the two standard criteria chosen (AHA and Melbourne Assessment).
Study: NCT01965951

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized Plasticity-based Adaptive Cognitive Training
Description: Computerized Plasticity-based Adaptive Cognitive Training requiring a total maximum of 39 treatment sessions, 4-5 times weekly, \~30 mins each session.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Commercially available computerized training
Description: Commercially available computerized training requiring a total maximum of 39 treatment sessions, 4-5 times weekly, \~30 mins each session.
Study: NCT00684294

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TGFβ2 Antisense-GMCSF Gene Modified Autologous Tumor Cell (TAG) Vaccine
Description: Patients with solid tumors will receive TAG Vaccine 1 x 10\^7 cells/ injection or TAG Vaccine 2.5 X 10\^7 cells/injection once a month for up to 12 doses via intradermal injection as long as sufficient material is available. Selection of cohort is dependent on the amount of tumor cell yield following harvest and processing.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TGFβ2 Antisense-GMCSF Gene Modified Autologous Tumor Cell (TAG) Vaccine
Description: Patients with solid tumors will receive TAG Vaccine 1 x 10\^7 cells/ injection or TAG Vaccine 2.5 X 10\^7 cells/injection once a month for up to 12 doses via intradermal injection as long as sufficient material is available. Selection of cohort is dependent on the amount of tumor cell yield following harvest and processing.
Study: NCT02144337

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Steps To Active Kids (STAK) programme
Description: Intervention described in Arm/Group Description.
Study: NCT01435642

Intervention type: OTHER
Intervention: No treatment given
Description: Subject will fill out a questionnaire when entering the non-interventional study
Study: NCT03684785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cavrotolimod
Description: Intratumorally dosed cavrotolimod.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cavrotolimod
Description: Intratumorally dosed cavrotolimod.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cavrotolimod
Description: Intratumorally dosed cavrotolimod.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cavrotolimod
Description: Intratumorally dosed cavrotolimod.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cavrotolimod
Description: Intratumorally dosed cavrotolimod.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cavrotolimod
Description: Intratumorally dosed cavrotolimod.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab dosing as per the US prescribing information.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab dosing as per the US prescribing information.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab dosing as per the US prescribing information.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab dosing as per the US prescribing information.
Study: NCT02905656

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Brief Advice
Description: Psychoeducation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Guides participants toward choosing to make a change in their behavior with a collaborative conversation.
Study: NCT03684785

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab dosing as per the US prescribing information.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab dosing as per the US prescribing information.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Cemiplimab dosing as per the US prescribing information.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cavrotolimod
Description: Subcutaneously dosed cavrotolimod